within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A08A_AntiobesityPreparationsExclDietProducts.A08AA11_Lorcaserin;

model Lorcaserin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.697,
    Cl = 5.916666666666666e-06,
    adminDuration = 600,
    adminMass = 10 / 1000000,
    adminCount = 1,
    Vd = 0.135,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.006233333333333333,
    Tlag = 9.96);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Lorcaserin</td></tr><tr><td>ATC code:</td><td>A08AA11</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>10</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>135</td><td>L</td></tr>
    <tr><td>clearance:</td><td>21.3</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Lorcaserin is a selective serotonin 2C receptor agonist that was used as an anti-obesity agent to promote weight loss by decreasing appetite. It was approved for use in the United States but was withdrawn from the market in 2020 due to concerns over an increased risk of cancer.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects after oral administration, based on population PK modeling.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.A.A08AA11 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Lorcaserin;
